Cereno Scientific

Raymond Benza will speak in several sessions about pulmonary hypertension (PAH) and its pathophysiology & pathogenesis; as well as chairing sessions and panel discussions. Björn Dahlöf, Chief Medical Officer (CMO) at Cereno, will speak in a presentation titled “Targeting Histone Deacetylase (HDAC) inhibition for pulmonary hypertension” in the session ‘Novel drug & device therapies’ as well as participate in a panel discussion, chaired by Anna Hemnes & Raymond Benza.

“This is a high-profile event in the field of pulmonary hypertension, and it is a great opportunity for Cereno to be seen by influential people from the pharma industry, regulators, and clinicians. I am looking forward to sharing insights on our drug candidate CS1 as an HDAC inhibitor in PAH, as well as learning from the best in the field,” commented Björn Dahlöf, CMO at Cereno.

The 8th Annual Drug Discovery & Development Symposium for Pulmonary Hypertension arranged by the Pulmonary Vascular Research Institute (PVRI) will be held on July 10-11, 2023, in Bethesda, Washington D.C., MD, US. The event is by invitation only and brings together leading scientists, clinicians, pharma professionals, and regulators in the field of pulmonary vascular disease and clinical trial design. The organizers describe it as a unique forum for sharing cutting-edge science, with a faculty of exceptional expertise and achievement. The hope is to influence the development of therapies and improve patients’ lives.

For further information, please contact:

Jonas Fogelberg, Interim CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.